Upfront Briefing
Roche ran the table Monday. First it put $700M behind Nurix's BTK degrader bexobrutideg — a co-dev, co-commercial pact that runs from CLL out into immunology and neurology. Then it lined up a petrelintide-enicepatide combo trial, turning its obesity book into a two-shot story. Behind the headline, ADA kept the obesity firehose on full blast: survodutide's efficacy is real, but a 19% dropout keeps the tolerability bears fed. The tape? Defensives held while higher-beta biotech got reminded Friday can still bite — chips dragged the broad market to its worst day since October.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,383.7 |
(2.6%) |
7.7% |
| Nasdaq 100 |
28,957.6 |
(4.8%) |
14.9% |
| Russell 2000 |
2,833.5 |
(3.5%) |
13.0% |
| Healthcare (XLV) |
153.0 |
0.6% |
(1.6%) |
| Biotech (XBI) |
128.7 |
(3.6%) |
5.9% |
| Nasdaq Biotech (NBI) |
5,842.0 |
(1.7%) |
2.4% |
| Clinical Trials (BBC) |
40.7 |
(5.3%) |
8.1% |
|
- Healthcare (XLV) was the tape's lone green box, up 0.6%, as ADA wrapped in New Orleans; higher-beta biotech sold off, with XBI down 3.6% and BBC down 5.3% (the day's worst) — a clean defensive rotation.
- The broad tape logged its worst day since October: a chip-led rout (Broadcom, Nvidia, Marvell, Micron) sank the Nasdaq 100 4.8% and the S&P 500 2.6%, while Treasury yields jumped back above 5% after May payrolls landed at 172k vs ~80k expected, reviving rate-hike fears.
- Market data: U.S. cash close Friday, 5 June 2026.
The Big 3
|
1
|
Nurix, Roche partner on BTK degrader bexobrutideg
|
- Bexobrutideg, also known as NX-5948, is headed into a global Roche collaboration spanning malignant hematology, immunology and neurology, with co-development and co-commercialization rights.
- Why it matters: $700M up front, up to $2.3B in milestones, a 50/50 U.S. profit split and ex-U.S. royalties — for a company Nurix's size, that's a balance-sheet reset, not a line item. The tell: Roche isn't renting one CLL asset, it's planting a flag across hematology, immunology and neurology, wagering that a degrader which destroys BTK beats the covalent inhibitors that only block it. The catch — Nurix now carries 40% of dev costs, so the runway gets a workout and execution risk rides a freshly two-sided P&L. Own the re-rate, watch the burn.
- Source: PR
- More: PR
|
|
2
|
Survodutide data sharpen efficacy-vs-tolerability debate
|
- Survodutide's Phase 3 ADA data paired a 34% visceral- and 63% liver-fat reduction with a reported 19% discontinuation rate over side effects.
- Why it matters: The fat-loss numbers are loud, but the stock-moving line is that 19% dropout. In a class where Lilly and Novo are setting the tolerability bar, a one-in-five quit rate caps the commercial ceiling no matter how clean the visceral- and liver-fat optics look. The wrinkle is positioning: Boehringer and Zealand are steering survodutide at MASLD/MASH, where the bar is organ damage, not scale weight — a lane that pays for efficacy and forgives some GI noise. Read it as a MASH play wearing an obesity headline, with Madrigal's resmetirom the real comp.
-
Source:
Endpoints
-
More:
Zealand;
Boehringer;
PR
|
| 3 | Roche advances petrelintide combo obesity strategy |
- Petrelintide plus enicepatide is now headed for a Phase 2 combo trial this year after Phase 2 ZUPREME-1 data supported petrelintide in overweight and obesity.
-
Why it matters: Roche is stitching petrelintide and enicepatide into one combo program — amylin plus its CT-388 incretin — with the Phase 2 starting this year. That's Roche telling the Street it won't try to out-monotherapy Lilly and Novo; it'll come at the class on tolerability and a differentiated combo instead. ZUPREME-1 dealt petrelintide a clean enough card to justify the move. The risk is proof and timing: this is a trial plan riding Phase 2 data, not a readout, and the combo has to actually show synergy before it dents Zepbound/Wegovy economics. Promising setup, catalyst still a year out.
-
Source:
Endpoints
-
More:
BioSpace; PR; Fierce Biotech
|
Everything Else that broke
- Sanofi won EU approval for subcutaneous Sarclisa via the CirCLIQ on-body injector in multiple myeloma. — PR
- Amphista cleared its IND for AMX-883, a BRD9 degrader in AML, with clinic entry slated for H2 2026. — PR
- Novo said CagriSema 2.4 mg / 2.4 mg cut HbA1c and weight across three Phase 3 REIMAGINE studies. — PR
- Lilly's retatrutide posted 28.3% mean weight loss at 80 weeks in Phase 3 TRIUMPH-1 (45.3% of patients ≥30%), with TRANSCEND-T2D-1 published simultaneously in The Lancet. — BioSpace
- Pfizer’s berobenatide added mid-stage support for monthly dosing in obesity and diabetes. — Endpoints
- Wegovy pill prescriptions topped 3 million since Jan. 5, with most new scripts from GLP-1 newcomers. — PR
- Amgen said Repatha cut first major cardiovascular events by 29% in high-risk diabetes. — PR
- Sciwind said ecnoglutide delivered 35% greater weight loss than semaglutide in a head-to-head study. — PR
- OriCell won NMPA clearance for a confirmatory Phase II trial of GPC3 CAR-T Ori-C101 in HCC. — PR
- Dayspring posted positive topline Phase II results for CG2001 in androgenetic alopecia. — PR
- Cullinan showed initial CLN-978 data with clinical benefit, including remissions, in SLE and RA. — PR
- Biomea expanded the Phase I BMF-650 study and shared new ADA data for icovamenib. — PR
- FDA’s rare-disease framework is expanding pathways while leaving implementation questions for bespoke programs. — BioSpace
- Anti-China biotech proposals are gaining traction in Washington, raising cross-border sourcing and development risk. — Endpoints
- House appropriators told the FDA to speed IND sign-offs to accelerate new trial starts. — Endpoints
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
Nurix and Roche formed a global bexobrutideg collaboration across hematology, immunology and neurology (see The Big 3). — PR
-
GNI Group agreed to acquire Ayumi Pharmaceutical Holdings to expand its commercial platform in Japan. — PR
VC / Private Financings
- No notable VC / private financings in the last 24 hours.
IPOs / Follow-Ons
- Jade Biosciences closed a $172.5M public offering of 11.5M shares priced at $15.00. — PR
- VolitionRx priced a $4.6M public offering with warrants that could add up to $2.3M. — PR
Academic Corner - Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. — Nature Medicine
- Survodutide Once Weekly for the Treatment of Adults with Obesity. — NEJM
|
